Generated by AI
Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making. The company focuses primarily on dermatologic cancers, including melanoma and cutaneous squamous cell carcinoma, while also serving gastroenterology, ophthalmology, and certain mental health applications. Its portfolio includes tests used to help assess risk, refine diagnosis, and guide treatment choices through clinically actionable genomic and molecular information. Castle Biosciences works with physicians, specialty clinics, hospitals, and health systems that rely on specialized testing to better manage complex diseases and personalize care. The company’s role in the market centers on translating laboratory science into practical tools that can improve how patients are evaluated and treated across several high-need medical areas.
Website1500 W. Parkwood Ave
Friendswood, TX, 77546
United States
The latest articles about CSTL.
Castle Biosciences (CSTL) came into focus for investors after management raised full year 2026 revenue guidance to a range of US$385 million to US$395 million, citing higher TissueCypher test volumes and better pricing. The raised guidance arrived alongside a share price that has been climbing in recent months, with a 90 day share price return of 16.44% and a 30 day share price return of 4.90%. However, the year to date share price return is still down 10.51% and the 5 year total shareholder...
Summary of Nov 4's posts. Generated by AI.
Summary of Aug 5's posts. Generated by AI.
Summary of Jul 7's posts. Generated by AI.
Investors talking about CSTL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.